Phase 2 Chronic Rhinosinusitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 60 years of age.
- People who are scheduled to have one of the following sinus procedures: functional endoscopic sinus surgery, endoscopic turbinoplasty, or endoscopic septoplasty.
- People who have been diagnosed with chronic sinusitis and/or nasal polyps that require surgery.
- People who are able and willing to sign a written consent form agreeing to take part.
- People who are able and willing to attend all required appointments and follow the study treatment plan.
Who may not be able to join:
- People with a known allergy to triamcinolone acetonide (a type of steroid medication).
- People with a known allergy to any ingredient in the special nanocapsule formula used in the study.
- People for whom steroid treatment is not medically safe for whole-body use.
- People who have a severe active infection in the nose or sinuses at the time of joining the trial.
- People who are pregnant or breastfeeding (confirm with trial site).
- People with diabetes that is not well controlled, where steroid exposure may be a concern (confirm with trial site).
- People who have a weakened immune system or are taking medication that suppresses the immune system.
- People who have recently used steroid medication (by mouth, injection, or nasal spray) within the timeframe set out by the study rules (confirm with trial site for exact timeframe).
- People who are currently taking part in another clinical trial.
- People who have a medical or mental health condition that may affect their ability to consent, follow the treatment plan, or attend follow-up visits.
- People who are unable to complete the required questionnaires or attend all follow-up visits.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sally Mansour Helmy, Deraya University
Phone: +20 102 692 0921
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Lund-Kennedy Endoscopic Score; Change in 22-Item Sinonasal Outcome Test Score (SNOT-22)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.